{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-115287","form_type":"8-K","ticker":"COLL","cik":"0001267565","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.932538+00:00","generated_at":"2026-05-30T03:19:56.439871+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Collegium posts record Q3 revenue $159.3M, up 17%; names Vikram Karnani CEO","bullets":["Q3 net revenue $159.3M (record), up 17% YoY; GAAP net income $9.3M ($0.27 diluted EPS).","Adjusted EBITDA $105.1M, up 18% YoY; non-GAAP adjusted EPS $1.61.","Reaffirms FY2024 guidance: product revenue $620-635M, adjusted EBITDA $395-405M.","Appoints Vikram Karnani as President and CEO effective Nov 12, 2024; Heffernan remains Chairman.","Closed Ironshore acquisition (Jornay PM) in Sep 2024, entering ADHD neurology."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-115287","json":"https://secwatch.observer/filing/0001104659-24-115287.json","markdown":"https://secwatch.observer/filing/0001104659-24-115287.md","text":"https://secwatch.observer/filing/0001104659-24-115287.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1267565/000110465924115287/0001104659-24-115287-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1267565/000110465924115287/tm2427748d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:19:56.439871+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"72bed20dc9","claim":"Vikram Karnani was appointed as President and Chief Executive Officer at COLLEGIUM PHARMACEUTICAL, INC.","evidence_excerpt":"the Board of Directors (the “Board”) of the Company appointed Vikram Karnani to serve as the Company’s President and Chief Executive Officer, effective November 12, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465924115287/0001104659-24-115287-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"abc93d740f","claim":"Vikram Karnani was appointed as member of the Board at COLLEGIUM PHARMACEUTICAL, INC.","evidence_excerpt":"Concurrently with his appointment as President and Chief Executive Officer and effective as of the Effective Date, Mr. Karnani will be appointed to serve as a member of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465924115287/0001104659-24-115287-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"member of the Board"}],"fact_type":"executive_change"},{"claim_id":"cfc4a15cc5","claim":"Michael Heffernan changed role as President and Chief Executive Officer at COLLEGIUM PHARMACEUTICAL, INC.","evidence_excerpt":"succeeding Michael Heffernan, who will continue to serve as the Company’s Chairman of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465924115287/0001104659-24-115287-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"succeeded"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}